Panelists discuss how biomarker development in anal cancer remains limited with PD-L1 status not influencing treatment ...

Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, reflects on the impact of HER2 identification on the breast cancer ...

As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2 targeted therapies to remain integral to growth.

The trial will include patients with non-small cell lung, colorectal, head and neck, and cutaneous cancers with EGFR amplification.